Loading…
Aptevo Therapeutics Inc. is projected to decline to $4.65 by 2027, a -4% move from its current price of $4.84. APVO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.66 | $4.84 | $5.03 | +0.04% |
| May 30 | $4.60 | $4.84 | $5.11 | +0.07% |
| May 31 | $4.54 | $4.85 | $5.17 | +0.11% |
| Jun 1 | $4.50 | $4.85 | $5.22 | +0.15% |
| Jun 2 | $4.46 | $4.85 | $5.27 | +0.19% |
| Jun 3 | $4.43 | $4.85 | $5.31 | +0.22% |
| Jun 4 | $4.40 | $4.85 | $5.36 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.40 | $4.85 | $5.36 | +0.26% |
| Week 2 | $4.23 | $4.87 | $5.59 | +0.52% |
| Week 3 | $4.11 | $4.88 | $5.79 | +0.79% |
| Week 4 | $4.02 | $4.89 | $5.96 | +1.05% |
| Week 5 | $3.93 | $4.90 | $6.11 | +1.31% |
| Week 6 | $3.86 | $4.92 | $6.26 | +1.58% |
| Week 7 | $3.80 | $4.93 | $6.40 | +1.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aptevo Therapeutics Inc. is a clinical-stage research and development biotechnology company focusing on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using the ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myeloid leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
APVO is a healthcare sector stock. It is currently priced at $4.95 with a market capitalization of $6.17M and is ranked 5286 by market cap.
The near-term price outlook shows a mix of neutral sentiment and a narrow price path, while longer horizons reflect growing upside potential according to the latest forecast data. The stock sits within a 30-day range that informs a short- to mid-term view, alongside current price levels and market positioning.
A major floor 21.3% below — a decisive break under it would weaken the trend.
The nearest floor, 8.1% below — buyers have tended to step in here.
The nearest ceiling, 15.9% above — a clean break opens room to run.
A major ceiling 103.1% above — clearing it would confirm fresh momentum.
Key APVO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APVO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.85 | Sell | $4.84 | Sell |
| MA 10 | $4.77 | Buy | $4.83 | Buy |
| MA 20 | $4.88 | Sell | $4.85 | Sell |
| MA 50 | $4.74 | Buy | $5.36 | Sell |
| MA 100 | $6.06 | Sell | $17.15 | Sell |
| MA 200 | $16.25 | Sell | $1,783.10 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.92 | Neutral |
| Stoch RSI (14) | 69.09 | Neutral |
| CCI (20) | -15.58 | Neutral |
| Williams %R (14) | -33.90 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -2.62 | Sell |
| Bollinger %B (20,2) | 0.46 | Neutral |
| Stochastic %K (14) | 66.10 | Neutral |
| TRIX (15) | -0.10 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 49.40 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 4.99 | Sell |
| ADX (14) | 10.71 | Neutral |
| ATR (14) | 0.14 | Info |
Near-term technical picture shows bullish sentiment with RSI14 at 50. The 50-day simple moving average is $4.73 and the 200-day simple moving average is $16.59, indicating potential resistance above recent levels.
Key near-term levels include a support at $4.45 and a resistance at $5.61. The 30-day range spans from $3.81 to $6.43, illustrating a relatively wide trading band in the near term. Annualized volatility stands at 80%, underscoring substantial price fluctuation within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.96 | $4.84 | $5.80 | 0% | Neutral | |
| $3.56 | $4.65 | $6.51 | -4% | Neutral | |
| $3.70 | $5.03 | $7.37 | +4% | Neutral | |
| $4.23 | $5.94 | $9.03 | +23% | Bullish | |
| $4.45 | $6.43 | $10.08 | +33% | Bullish | |
| $3.78 | $5.61 | $9.02 | +16% | Neutral | |
| $3.60 | $5.48 | $9.03 | +13% | Neutral | |
| $3.73 | $5.81 | $9.78 | +20% | Bullish | |
| $3.89 | $6.22 | $10.67 | +28% | Bullish | |
| $4.57 | $7.45 | $13.02 | +54% | Bullish | |
| $4.77 | $8.62 | $16.26 | +78% | Bullish | |
| $5.74 | $12.53 | $26.32 | +159% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.96 | $4.84 | $5.70 | +0.00% |
| June 2026 | $4.21 | $4.98 | $6.06 | +2.86% |
| July 2026 | $4.18 | $5.01 | $6.21 | +0.59% |
| August 2026 | $3.97 | $4.79 | $6.02 | -4.29% |
| September 2026 | $3.94 | $4.80 | $6.10 | +0.18% |
| October 2026 | $4.02 | $4.93 | $6.34 | +2.78% |
| November 2026 | $3.84 | $4.73 | $6.13 | -4.12% |
| December 2026 | $3.58 | $4.44 | $5.80 | -6.15% |
Click any year to see its month-by-month APVO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Aptevo Therapeutics Inc.'s 2026 outlook centres on $4.84, within a $3.96 to $5.80 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, APVO could reach as high as $6.51, with a base case around $4.65 and support toward $3.56 — roughly -4% from $4.84. Price action looks broadly range-bound.
Expect APVO to range from $3.70 to $7.37 through 2028. The $5.03 average target implies a +4% move from current prices. That is up +8% on the projected 2027 average. A consolidation phase looks the most probable path here.
The APVO price prediction for 2029 points to an average of $5.94 (low $4.23, high $9.03) — a potential gain of +23% on today's $4.84. Momentum favours further upside here.
In 2030, APVO is projected to trade between $4.45 and $10.08, averaging $6.43 — a potential gain of +33% from today's $4.84. That is up +8% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Aptevo Therapeutics Inc.'s 2031 outlook centres on $5.61, within a $3.78 to $9.02 range. That is -13% versus the projected 2030 average. That marks a +16% change versus current levels. Price action looks broadly range-bound.
By 2032, APVO could reach as high as $9.03, with a base case around $5.48 and support toward $3.60 — roughly +13% from $4.84. A consolidation phase looks the most probable path here.
Expect APVO to range from $3.73 to $9.78 through 2033. The $5.81 average target implies a +20% move from current prices. That is up +6% on the projected 2032 average. Momentum favours further upside here.
The APVO price prediction for 2034 points to an average of $6.22 (low $3.89, high $10.67) — a potential gain of +28% on today's $4.84. Buyers look set to stay in control over this stretch.
In 2035, APVO is projected to trade between $4.57 and $13.02, averaging $7.45 — a potential gain of +54% from today's $4.84. That is up +20% on the projected 2034 average. Momentum favours further upside here.
Aptevo Therapeutics Inc.'s 2040 outlook centres on $8.62, within a $4.77 to $16.26 range. That is up +16% on the projected 2035 average. That marks a +78% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, APVO could reach as high as $26.32, with a base case around $12.53 and support toward $5.74 — roughly +159% from $4.84. Momentum favours further upside here.
Investing $1,000 in APVO today (≈ 206.61157 APVO) could be worth
$2,587.99
+$1,587.99 (+159%) by 2050 · US Dollar
Based on the average projected APVO price of $12.53 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APVOwould be worth at today's price.
$1,000 invested in APVO on May 27, 2025 (≈ 11.29178 APVO) would be worth
$54.65
-$945.35 (-94.5%) today · 0.05× · US Dollar
Based on a APVO entry price of $88.56 vs. today's $4.84.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.55 | $1,062.57 | +6.3% |
| 1 month ago | $4.92 | $983.74 | -1.6% |
| 3 months ago | $7.35 | $658.5 | -34.1% |
| 6 months ago | $24.84 | $194.85 | -80.5% |
| 1 year ago | $88.56 | $54.65 | -94.5% |
| All time (5.0y) ago | $15,325,992 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APVO forecast.
Our base-case forecast reaches $9.70 around 2050.
Implied market cap at $9.70: $12.09M
The multi-year forecast paints a path of gradual upside, with the 2026 average price at $4.95 and a neutral sentiment. By 2029 the average is $6.13 with a bullish tilt continuing into 2030, where the average is $6.66 and the sentiment remains bullish with a 34.6% ROI.
Beyond 2030, the forecast shows continued positive momentum: 2031 avg $5.68 (14.8% ROI), 2032 avg $5.60 (13.1% ROI), 2033 avg $5.98 (20.8% ROI), 2034 avg $6.30 (27.2% ROI), 2035 avg $7.70 (55.5% ROI). In the long run, 2040 avg $8.81 (77.9% ROI) and 2050 avg $12.70 (156.6% ROI) with bullish sentiment. These are estimates, not guarantees, and reflect varying earnings, market conditions, and execution risks over time.
Tap a question to reveal the answer.
2030: min $4.54, avg $6.66, max $10.62; roiPct 34.6; sentiment BULLISH.
The forecast shows years with neutral and positive returns, including 0% in 2026, -3.8% in 2027, 3.8% in 2028, 23.9% in 2029, 34.6% in 2030, 14.8% in 2031, 13.1% in 2032, 20.8% in 2033, 27.2% in 2034, 55.5% in 2035, 77.9% in 2040, and 156.6% in 2050. These are estimates and carry investment risk; they do not guarantee outcomes.
Yes—the 2050 forecast lists a max of $27.45 with a 156.6% ROI and bullish sentiment.
Current price is $4.95 and market capitalization is $6.17M.
Near-term picture shows bullish sentiment; RSI 14 is 50, SMA50 is $4.73, SMA200 is $16.59. Support is $4.45 and resistance is $5.61; 30-day range is $3.81 to $6.43; annualized volatility is 80%.
Aptevo Therapeutics Inc. Community Discussion
0Share your Aptevo Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.